In Brief: Gull Laboratories/Fresenius AG
This article was originally published in The Gray Sheet
Executive Summary
Gull Laboratories/Fresenius AG: Gull plans to acquire the diagnostics operations of Germany-based Fresenius Intensive Care and Diagnostics Division in a transaction expected to close in the second quarter of calendar 1997. Consolidation of the two diagnostics businesses is expected to increase Gull's worldwide revenues by 40% and accelerate the anticipated 1997 launch of the Thrombus Precursor Protein (TpP), GeneSTAR program, "and other new infectious disease and autoimmune products," Gull says. For the first nine months of fiscal 1996 (ends Dec. 31), Gull generated $13 mil. in sales. Terms of the deal were not disclosed...